San Diego, CA -- (SBWIRE) -- 07/18/2018 -- The takeover of Juniper Pharmaceuticals, Inc. is under investigation concerning whether the takeover of Juniper Pharmaceuticals, Inc. by Catalent, Inc is unfair to NASDAQ: JNP stockholders.

Investors who purchased shares of Juniper Pharmaceuticals, Inc. (NASDAQ: JNP) and currently hold any of those NASDAQ: JNP shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain officers and directors of Juniper Pharmaceuticals, Inc. breached their fiduciary duties owed to NASDAQ: JNP investors in connection with the proposed acquisition.

On July 3, 2018, Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) announced it has entered into an agreement with Catalent, Inc. for Catalent to acquire all of the outstanding shares of Juniper Pharmaceuticals, Inc. (NASDAQ: JNP) at a price of $11.50 per share in cash.

However, given that at least one analyst has set the high target price for NASDAQ:JNP shares at $20.00 per share, the investigation concerns whether the offer is unfair to NASDAQ: JNP stockholders. More specifically, the investigation concerns whether the Juniper Pharmaceuticals Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

On July 17, 2018, NASDAQ: JNP shares closed at $11.45 per share.

Those who are current investors in Juniper Pharmaceuticals, Inc. (NASDAQ: JNP) shares have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com